Stock Movers GSK Up, Mercedes Soars, Equinor Slips
Oct 29, 2025
Chloe Melle, a Bloomberg reporter specializing in European corporate earnings, shares insights on GSK's positive forecast bolstered by its HIV and immunology products. She also discusses Mercedes-Benz's robust margin improvement and its ambitious €2 billion share buyback plan despite potential risks from U.S. tariffs and a Chinese economic slowdown. Additionally, Melle highlights Equinor's disappointing Q3 earnings amid softening oil prices, revealing the challenges facing energy firms in a volatile market.
AI Snips
Chapters
Transcript
Episode notes
GSK's Upside From HIV, Vaccines
- GSK upgraded its profit and sales guidance driven by strong HIV and immunology medicine sales and better-than-expected vaccines performance.
- Investors appear reassured that GSK can hit its £40 billion sales target by 2031 despite pipeline and generic-competition risks.
Priorities For GSK's New CEO
- Focus on pipeline renewal and tariff negotiations as near-term priorities for incoming CEO Luke Miles.
- Address generic competition and pursue deals like peers to preserve future growth.
Mercedes Signals Strength But Faces Risks
- Mercedes confirmed its outlook and launched a €2 billion buyback, signaling confidence in cash generation after margin improvement.
- Still, China weakness and US tariff costs mean risks remain for luxury auto demand and margins.